Login Register Cart 0
Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Design, Optimization and Characterization of Combined Ethosomal Transdermal Patch of Glimepiride and Duloxetine Drug Regimen for Diabetes and Associated Neuropathic Pain Management

Author(s): Eswar kumar Aouta* and Chinam Niranjan Patra

Volume 17, Issue 5, 2022

Published on: 25 August, 2022

Page: [359 - 368] Pages: 10

DOI: 10.2174/1574885517666220525122859

Price: $65

Abstract

Background: Diabetic neuropathic pain is the most prevalent type of neuropathic pain and a major consequence of diabetes. A wide range of medications, whether administered alone or in combination, have been found to dramatically decrease neuropathic pain.

Objective: This study aimed to develop the glimepiride (GLM) and duloxetine (DUL) ethosomal transdermal drug delivery patches to prolong and improve the discharge of the drug regimen to treat diabetics as well as neuropathic pain associated with it.

Methods: Using the solvent casting method, DUL and GLM ethosomal dispersions were formulated by a 32 factorial design. A total of nine formulations were developed considering ethanol (X1) and phospholipid (X2) independent factors, and the formulation was optimized based on entrapment efficiency (Y1) and particle size (Y2). Moreover, size, surface charge, and % entrapment efficiency were characterized. The ethosomal formulations converted into patches were characterized by thickness, folding endurance, in vitro penetrability, and ex vivo skin permeability.

Results: The results of thickness, % moisture content, % moisture uptake, and folding endurance were in an acceptable range for all formulations. Based on the in vitro penetrability and ex vivo skin permeability profile, formulation F9 was considered optimized, extending the cumulative drug release of more than 60 % up to 24hrs and skin permeability of more than 200 μg/cm2.

Conclusion: The investigation showed that the medication increment transdermal fix of GLM and DUL was a promising path for the therapeutic management of diabetes and diabetic neuropathic pain.

Keywords: Duloxetine, ethosomes, glimepiride, transdermal delivery, phospholipid 32 factorial design, ex-vivo permeability.

« Previous Next »
Graphical Abstract

[1]
Ah Y-C, Choi J-K, Choi Y-K, Ki H-M, Bae J-H. A novel transdermal patch incorporating meloxicam: In vitro and in vivo characterization. Int J Pharm 2010; 385(1-2): 12-9.
[http://dx.doi.org/10.1016/j.ijpharm.2009.10.013] [PMID: 19833177]
[2]
Cho C-W, Choi J-S, Yang KH, Shin SC. Enhanced transdermal controlled delivery of glimepiride from the ethylene-vinyl acetate matrix. Drug Deliv 2009; 16(6): 320-30.
[http://dx.doi.org/10.1080/10717540903031084] [PMID: 19606946]
[3]
Patel K, Padhye S, Nagarsenker M. Duloxetine HCl lipid nanoparticles: Preparation, characterization, and dosage form design. AAPS PharmSciTech 2012; 13(1): 125-33.
[http://dx.doi.org/10.1208/s12249-011-9727-6] [PMID: 22167415]
[4]
Cevc G, Schätzlein A, Blume G. Transdermal drug carriers: Basic properties, optimization and transfer efficiency in the case of epicutaneously applied peptides. J Control Release 1995; 36(1-2): 3-16.
[http://dx.doi.org/10.1016/0168-3659(95)00056-E]
[5]
Cohen K, Shinkazh N, Frank J, Israel I, Fellner C. Pharmacological treatment of diabetic peripheral neuropathy. P&T 2015; 40(6): 372-88.
[PMID: 26045647]
[6]
Dave V, Kumar D, Lewis S, Paliwal S. Ethosome for enhanced transdermal drug delivery of aceclofenac. Int J Drug Deliv 2010; 2(1): 81-92.
[http://dx.doi.org/10.5138/ijdd.2010.0975.0215.02016]
[7]
Davis SN. The role of glimepiride in the effective management of Type 2 diabetes. J Diabetes Complications 2004; 18(6): 367-76.
[http://dx.doi.org/10.1016/j.jdiacomp.2004.07.001] [PMID: 15531188]
[8]
Duangjit S, Opanasopit P, Rojanarata T, Ngawhirunpat T. Characterization and in vitro skin permeation of meloxicam-loaded liposomes versus transfersomes. J Drug Deliv 2011; 2011: 418316.
[http://dx.doi.org/10.1155/2011/418316] [PMID: 21490750]
[9]
Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain NK. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J Control Release 2007; 123(2): 148-54.
[http://dx.doi.org/10.1016/j.jconrel.2007.08.005] [PMID: 17884226]
[10]
Dubey V, Mishra D, Nahar M, Jain V, Jain NK. Enhanced transdermal delivery of an anti-HIV agent via ethanolic liposomes. Nanomedicine 2010; 6(4): 590-6.
[http://dx.doi.org/10.1016/j.nano.2010.01.002] [PMID: 20093197]
[11]
Eeman M, Deleu M. From biological membranes to biomimetic model membranes. Biotechnol Agron Soc Environ 2010; 14(4): 719-36.
[12]
Kumar E, Patra CN. Development characterization optimization of ethosome containing duloxetine for transdermal delivery. Int J Pharm Sci Res 2020; 11(2): 652-9.
[http://dx.doi.org/10.13040/IJPSR.0975-823]
[13]
Liu XX. Rao Yf, Liang WQ. Study on transdermal penetration of ethinyl estradiol ethosome gel. Chung Kuo Yao Hsueh Tsa Chih 2006; 41(4): 284-6.
[14]
Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes - novel vesicular carriers for enhanced delivery: Characterization and skin penetration properties. J Control Release 2000; 65(3): 403-18.
[http://dx.doi.org/10.1016/S0168-3659(99)00222-9] [PMID: 10699298]
[15]
Liu X, Liu H, Liu J, et al. Preparation of a ligustrazine ethosome patch and its evaluation in vitro and in vivo. Int J Nanomedicine 2011; 6: 241-7.
[http://dx.doi.org/10.2147/IJN.S16044] [PMID: 21499422]
[16]
Dayan N, Touitou E. Carriers for skin delivery of trihexyphenidyl HCl: Ethosomes vs. liposomes. Biomaterials 2000; 21(18): 1879-85.
[http://dx.doi.org/10.1016/S0142-9612(00)00063-6] [PMID: 10919691]
[17]
Qiu L, Wang Q, Zhang J, Huo NB. Studies on inhibition of crystallization and in vitro percutaneous absorption of tetramethylpyrazine transdermal delivery system. Chung Kuo Yao Hsueh Tsa Chih 2006; (21): 1642-6.
[18]
Jorge LL, Feres CC, Teles VE. Topical preparations for pain relief: Efficacy and patient adherence. J Pain Res 2010; 4: 11-24.
[http://dx.doi.org/10.2147/JPR.S9492] [PMID: 21386951]

Rights & Permissions Print Cite
Article Metrics
5
© 2024 Bentham Science Publishers | Privacy Policy